treatment stabilizes chronobiologic and cognitive symptoms in
Luis I. Brusco, Miguel M·rquez & Daniel P. Cardinali
Reprinted with the permission: Neuroendocrinology Letters 1998;
melatonin, Alzheimerís disease, cognitive impairment, sleep
OBJECTIVES: A retrospective study on the efficacy of melatonin
in treatment of sleep and cognitive disorders of Alzheimerís
disease was conducted.
Fourteen patients (8 females, 6 males), mean ± S.D. age 72 ±
9 years were included. All patients received 9 mg gelatin melatonin
capsules p.o. daily at bedtime for 22 to 35 months. Overall
quality of sleep was assessed from sleep logs filled in by the
patients or their caretakers. Neuropsychological evaluation
was performed by Functional Assessment Tool For Alzheimerís
Disease (FAST), Mini-Mental, Alzheimerís Disease Assessment
Scale (ADAS), and Mattisí and Blessedís scales. At diagnosis,
all patients had cognitive and neuroimaging alterations (cortical
and bitemporal atrophy) compatible with different evolutionary
stages of the disease.
At the time of assessment, a significant improvement of sleep
quality was found in all cases examined. There were no significant
differences between initial and present evaluation in scores
of FAST, Mini-Mental, and ADAS, and of Mattisí and Blessedís
scales. Clinically, the patients exhibited lack of progression
of the cognitive and behavioral signs of the disease during
the time they received melatonin. Sundowning was no longer detectable
in 12 patients and persisted, although attenuated, in 2 patients.
The results suggest that melatonin can be useful for treatment
of Alzheimerís disease.